Aviva
CCXI

Aviva’s ChemoCentryx, Inc. CCXI Stock Holding History

Aviva’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,023
Closed -$1.18M – 1007
2021
Q1 		$1.18M Sell
23,023
-817
-3% -$49.2K 0.01% 870
2020
Q4 		$1.48M Sell
23,840
-19,326
-45% -$1.11M 0.01% 770
2020
Q3 		$2.37M Buy
+43,166
New +$2.32M 0.01% 637

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aviva's CCXI Position: Q2 2021 in Review

Aviva sold out of ChemoCentryx, Inc. (CCXI) in Q2 2021, closing a stake of 23,023 shares — an estimated $1.18M sold.

Aviva first reported a position in CCXI in Q3 2020 and held it in 3 quarters. The position peaked at $2.37M in Q3 2020. 146 funds tracked by Wall St. Rank hold CCXI as of Q2 2021.

  • Aviva reported no remaining ChemoCentryx, Inc. position as of Q2 2021 after selling out during the quarter.
  • Aviva sold 23,023 ChemoCentryx, Inc. shares in Q2 2021, an estimated $1.18M.
  • Aviva first reported a position in ChemoCentryx, Inc. in Q3 2020 and held it in 3 quarters.
  • Aviva's ChemoCentryx, Inc. position peaked at $2.37M in Q3 2020.
  • 146 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.